Recombinant Human Thrombopoietin/TPO Protein, CF

Equivalent bioactivity of GMP(BT-TPO-GMP),Animal-Free (BT-TPO-AFL) and RUO (Catalog # BT-TPO) grades of RecombinantHuman Thrombopoietin/Tpoproteins as measured in a cellproliferation assay using MO7ehuman megakaryocytic leukemiccells (orange, green, red,respectively).

Recombinant Human Thrombopoietin/Tpo (Catalog # BT-TPO) stimulates proliferation in the MO7e human megakaryocytic leukemic cell line. The ED50 for this effect is 0.0500‑0.500 ng/mL.

2 μg/lane of Recombinant Human Thrombopoietin/Tpo Protein (Catalog # BT-TPO) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-19 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Thrombopoietin/TPO Protein, CF Summary

• Details of Functionality: Measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The ED₅₀ for this effect is 0.0500-0.500 ng/mL.
• Source: E. coli-derived human Thrombopoietin/Tpo protein
  Ser22-Leu195
• Accession #: NP_000451.1
• N-terminal Sequence: Ala-Ser22
• Protein/Peptide Type: Recombinant Proteins
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 18-19 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with Trehalose.
• Reconstitution Instructions: Reconstitute the 10 μg size at 100 μg/mL in water. Reconstitute all other sizes at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Thrombopoietin/TPO Protein, CF

• Megakaryocyte colony-stimulating factor
• Megakaryocyte growth and development factor
• megakaryocyte stimulating factor
• MGDF
• MGDFC-mpl ligand
• MKCSF
• MK-CSF
• ML
• MPL ligand
• MPLLG
• MPLLGMGC163194
• Myeloproliferative leukemia virus oncogene ligand
• THCYT1
• THPO
• thrombopoietin nirs variant 1
• Thrombopoietin
• Tpo
• TPOMKCSF

Background

Thrombopoietin (TPO) is a crucial regulator of hematopoietic stem cell (HSC) differentiation, maturation, and proliferation, as well as megakaryocytopoiesis and thrombopoiesis. TPO is often used in conjunction with Stem Cell Factor (SCF) and Flt-3 ligand in cell culture protocols to expand HSCs for bone marrow transplantation and cellular therapies. When combined with SCF and Flt-3 ligand, it promotes the differentiation of HSCs into megakaryocytes, leading to the production of platelets. It has shown promise in emerging cellular therapies for treating sickle cell disease, beta thalassemia, and other blood-related disorders. Moreover, TPO in combination with other cytokines is utilized in the generation of iNK cells, which have the potential to be incorporated into cellular immunotherapies.

Publications for Thrombopoietin/THPO (BT-TPO)(1)

Publication using BT-TPO

• Claiborne, D;Detwiler, Z;Docken, S;Borland, T;Cromer, D;Simkhovich, A;Ophinni, Y;Okawa, K;Bateson, T;Chen, T;Hudson, W;Trifonova, R;Davenport, M;Ho, T;Boutwell, C;Allen, T; High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection Nature communications 2025-01-07 [PMID: 39774003] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • NP_000451.1()